Therapeutic Asset Ratings
208 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
FUROSEMIDE
Solid Tumors
M.D. Anderson Cancer Center
P1/2
CC
(46)
Oric-114
Solid Tumors
ORIC Pharmaceuticals
P1/2
CC
(46)
Precemtabart Tocentecan
Solid Tumors
EMD Serono Research & Development Institute, Inc.
P1/2
CC
(46)
Retifanlimab
Solid Tumors
Incyte Corporation
P1/2
CC
(46)
rc48-adc
Solid Tumors
RemeGen Co., Ltd.
P1
CC
(44)
msc1936369b
Solid Tumors
Day One Biopharmaceuticals, Inc.
P1
CC
(41)
7mw4911
Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
P1/2
CC
(41)
8mw2311
Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
P1/2
CC
(41)
9mw2821
Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
P1/2
CC
(41)
abl103
Solid Tumors
ABL Bio, Inc.
P1/2
CC
(41)
asp0739
Solid Tumors
Astellas Pharma Global Development, Inc.
P1/2
CC
(41)
Atirmociclib
Solid Tumors
Pfizer
P1/2
CC
(41)
bi-1910
Solid Tumors
BioInvent International AB
P1/2
CC
(41)
cts2190 capsules
Solid Tumors
CytosinLab Therapeutics Co., Ltd.
P1/2
CC
(41)
Dcsz11
Solid Tumors
West China Hospital
P1/2
CC
(41)
f520
Solid Tumors
Shandong New Time Pharmaceutical Co., LTD
P1/2
CC
(41)
hb0052
Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
P1/2
CC
(41)
Hrs-4642
Solid Tumors
Henan Cancer Hospital
P1/2
CC
(41)
HUMAN LEUKOCYTE
Solid Tumors
Dipnarine Maharaj
P1/2
CC
(41)
Icp-723
Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
P1/2
CC
(41)
Incb177054
Solid Tumors
Incyte Corporation
P1/2
CC
(41)
Ivonescimab
Solid Tumors
GlaxoSmithKline
P1/2
CC
(41)
Jab-2485
Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
P1/2
CC
(41)
Jab-30355
Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
P1/2
CC
(41)
Panax Ginseng
Solid Tumors
M.D. Anderson Cancer Center
P1/2
CC
(41)
Showing 76 to 100 of 208 assets
Previous
Page 4 of 9
Next